Safety profile comparable to a traditional PPI-based triple therapy1,*
Adverse reactions occurring in ≥2% of clinical trial patients*
| Adverse Reactions | (n=346) n (%) | (n=348) n (%) | (n=345) n (%) |
|---|---|---|---|
| Diarrhea | 14 (4.0) | 18 (5.2) | 33 (9.6) |
| Altered sense of tastea | 16 (4.6) | 2 (0.6) | 21 (6.1) |
| Vulvovaginal candidiasisb | 11 (3.2) | 7 (2.0) | 5 (1.4) |
| Abdominal painc | 8 (2.3) | 9 (2.6) | 10 (2.9) |
| Headache | 9 (2.6) | 5 (1.4) | 5 (1.4) |
| Hypertensiond | 7 (2.0) | 4 (1.1) | 3 (0.9) |
| Nasopharyngitis | 1 (0.3) | 7 (2.0) | 3 (0.9) |
*This study was not designed to evaluate meaningful comparisons of the incidence of adverse reactions in the identified treatment groups.
aAltered sense of taste also includes taste disorder.
bVulvovaginal candidiasis includes: urogenital infection fungal, vulvovaginal candidiasis, vulvovaginal mycotic infection, vulvovaginal pruritus, pruritus genital, genital infection fungal.
cAbdominal pain includes: abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper.
dHypertension also includes blood pressure increased.
Few discontinuations due to adverse events
- 2.3% with VOQUEZNA Triple Pak, 0.9% with VOQUEZNA Dual Pak vs 1.2% with lansoprazole triple therapy